Growth PotentialJornay, acquired through the Ironshore Therapeutics transaction, has rapidly emerged as the company’s lead growth driver, with prescriptions growing 42% year-over-year in 2Q25, and 15% sequentially over 1Q25.
Market ExpansionWith expanded field force coverage, increasing market share, and exclusivity through at least 2032, Jornay remains early in its commercial trajectory and is well-positioned to contribute significantly to COLL's long-term growth, and pivot away from a solely pain-based company.
Shareholder ValueIn a testament to COLL's current strong financial position, the company announced a new $150M share buyback authorization.